Skip to main content

Progress Made Toward NASH Diagnosis and Drug Discovery

 A buildup of fat in the liver could cause an aggressive type of nonalcoholic fatty liver disease (NAFLD), called nonalcoholic steatohepatitis (NASH) which is a condition with liver inflammation and damage. Most of the time, it causes no symptoms and no problems, while in some worse cases, the fat causes inflammation and damages liver cells, affecting the normal function of the liver or even leading to cirrhosis. Though the second leading indication for liver transplantation in the United States, NASH has no FDA-approved treatments currently. This is drawing concerns from all stakeholders, including patients and providers, for which experts call for a great deal of focus on understanding and addressing this important liver disease that impacts clinical outcomes and the quality of life.

 

Diagnosis of NASH

 

Because NASH are asymptomatic until patients are identified at advanced stages, a liver biopsy remains the gold standard for making early predictive and definitive NASH diagnosis and staging. However, the liver biopsy is an invasive procedure that has several drawbacks, including sampling error, high expense, side effects like pain and bleeding, and the impracticability of performing liver biopsies on all NASH patients. All these unfavorable factors are prompting the technology for developing reliable, precise, and noninvasive NASH diagnostic approaches.

 

Biomarkers, as noninvasive and reliable alternatives to liver biopsy, contribute to the early diagnosis of NASH by indicating biological characteristics in a normal or pathologic process. Conventional NASH biomarkers like liver enzymes have different drawbacks. And currently, it's not possible to identify fibrosis and steatosis, to early diagnose NASH, or to predict the disease progression with one biomarker alone single test. There are many novel noninvasive tests are in development, and multi-omics biomarkers, including those focusing on microbiota, seem to be promising if only combinatorial methods were standardized and implemented.

 

Treatment of NASH

 

Though no pharmacologic therapy has been approved to treat NASH and clinical advice on treating this disease is more about lifestyle modification based on body weight and exercise, the NASH therapeutic pipeline is robust.

 

As a matter of fact, there are approximately dozens of projects for NASH drug development with different mechanisms. They are being investigated in various phases of drug development, some of which undoubtedly would come across setbacks but numerous drugs still are showing great promise for the potential to treat NASH. With different endpoints like a histological improvement, NASH resolution, prevention of progression to cirrhosis, and fibrosis stage regression, some NASH drugs are expected to be approved on the basis of relatively short-term studies. However, it's also pointed out that in the race of developing medical treatment of NASH, lifestyle modification is still the most effective treatment currently available for NASH patients.

 

Researchers have a positive attitude toward the future of NASH drug approval and look forward to receiving approval for at least one additional serum biomarker in recent years. Also, as NASH is a complex and multiorgan disease involving different mechanisms of action, experts indicated that it would be beneficial to have several approved drugs to tailor different treatments for different patients.

 

Labels:

Comments

Post a Comment

Popular posts from this blog

Primary Antibody vs. Secondary Antibody, How to Choose?

  Antibodies (or immunoglobulins) are Y -shaped glycoproteins released by the immune system  to detect and bind to "foreign" substances , known as " antigens ", triggering a cascade of actions to destroy these foreign invaders. Scientists would develop different antibodies for research use, which basically can be classified into primary and secondary antibodies . However, how to choose the right type of antibodies for different immunoassays in experiment procedures, such as western blotting (WB), enzyme-linked immunosorbent assays (ELISA), and immunoprecipitation (IP), is one of the most common questions for green hands in the laboratory.   P rimary A ntibod y vs. Secondary Antibody   Antibodies could be categorized into two types based on the binding capability and experimental applications— primary   antibodies   and  secondary antibodies.   The main difference between these two types of antibodies is that primary antibody binds specifically to ...
Post a Comment
Read more

How Haptens Differ from Antigens and Become Immunogens?

The  difference between antigens vs. haptens  is one the most concerning issues for people who are not familiar with them. As a matter of fact, antigens and haptens are similar in many ways. They are both molecules triggering immune responses and acting as antigenic agents. And they both work as immunogens and bind to antibodies although haptens in a different manner.   What distinguishes an antigen mostly from a hapten is that antigens are complete molecules spontaneously triggering immune response whereas haptens are fragmentary small molecules that are unable to elicit immune responses unless they are conjugated to a larger molecule, known as a carrier.   What are Antigens? Antigen s, including proteins, peptides, and polysaccharides, are immunogen   molecules  that can trigger immune response s or naturally bind to   immune   components . An antigen may have one or more epitopes, which are the determinants of recognition and binding to antibod...
Post a Comment
Read more

Single-cell Genomics Study Elucidates Human Cytomegalovirus Infection

  I nfection of β-herpesvirus h uman cytomegalovirus (HCMV) could be life-threatening or cause life-long suffering in the majority of humans. Moreover, the viral vertical transmission during pregnancy leads to most congenital birth defects. However, treatment and prevention options currently available are extremely   limited.   Challenges  in Studying HCMV–host Cell Interactions   More than 235 kbp of double-stranded DNA (dsDNA)  in HCMV make s the largest known genome of human herpesviruses. Besides, HCMV is similar to other herpesviruses with complicated transcriptional architecture, including alternative transcription start sites, alternative splicing events, and polycistronic transcripts. The complex transcriptional architecture enables strict temporal control of gene expression and the possibility of generating multiple distinct proteins from a single genomic locus. The complexity is further increased by host cellular heterogeneity and differences in i...
Post a Comment
Read more